Land: Israel
Sprog: engelsk
Kilde: Ministry of Health
MARIBAVIR
TAKEDA ISRAEL LTD
J05AX10
FILM COATED TABLETS
MARIBAVIR 200 MG
PER OS
Required
TAKEDA IRELAND LTD., IRELAND
MARIBAVIR
LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
2023-05-31
- Regulations (Preparations) Patient leaflet in accordance with the Pharmacists' 1986 This medicine is dispensed with a doctor’s prescription only Livtencity Film-coated tablets Active ingredient: maribavir 200 mg Inactive ingredients and allergens in this medicine: see section 2 under ‘Important information about some of this medicine’s ingredients’, and section 6 ‘Additional information'. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. What is this medicine intended for? Livtencity is indicated for the treatment of adults and pediatric patients (12 years of age and older weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease, that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. Therapeutic group: Antivirals Livtencity is an antiviral medicine against the CMV virus. 2. Before using this medicine Do not use this medicine if: You are sensitive (allergic) to the active ingredient or to any of the other ingredients in this medicine (see section 6). Special warnings about using this medicine Before using Livtencity, tell your doctor if: You are taking anticonvulsants You are using ganciclovir or valganciclovir. Concomitant use with Livtencity is not recommended. See section 'Interactions with other medicines'. Additional warnings Treatment failure due to resistance may occur during and after treatment with Livtencity. Disease relapse after treatment discontinuation may occur within 4-8 weeks after treatment discontinuation. In case of lack of response to treatment or disease relapse, your doctor should monitor CMV levels and check for viral resistance to the medicine. Læs hele dokumentet
1 1 NAME OF THE MEDICINAL PRODUCT LIVTENCITY ® 1.1 DOSAGE FORMS AND STRENGTHS Each film coated Tablet contains 200 mg maribavir. The film coated tablet is blue, oval shaped convex tablet debossed with “SHP” on one side and “620” on the other side. 2 THERAPUTIC INDICATION LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet _[see _ _Use in Specific Populations (8.4) and Clinical Studies (14)]_ . 3 DOSAGE AND ADMINISTRATION 3.1 Recommended Dosage The recommended dosage in adults and pediatric patients (12 years of age and older and weighing at least 35 kg) is 400 mg (two 200 mg tablets) taken orally twice daily with or without food _[see Use in Specific _ _Populations (8.4), Clinical Pharmacology (12.3) and Clinical Studies (14)]_ . 3.2 Dosage Adjustment When Coadministered with Anticonvulsants If LIVTENCITY is coadministered with carbamazepine, increase the dosage of LIVTENCITY to 800 mg (four 200 mg tablets) twice daily _[see Drug Interactions (7.3)]. _ If LIVTENCITY is coadministered with phenytoin or phenobarbital, increase the dosage of LIVTENCITY to 1,200 mg (six 200 mg tablets) twice daily _[see Drug Interactions (7.3)]. _ 3.3_ _Administration The immediate-release tablets can be taken as whole, dispersed or crushed tablets by mouth, or as dispersed tablets through a nasogastric or orogastric tube (French size 10 or larger). The suspension may be prepared ahead of time and stored under 25 °C for up to 8 hours. Administration of Dispersed Tablets or Crushed Tablets by Mouth 1. Place the appropriate number of tablets for the prescribed dose into a suitable container. If desired, the tablets may be crushed. Add the appropriate volume of drinking water (other liquids have not been tested) to make a suspension _(see Table 1 below)_ . Table 1 Læs hele dokumentet